Notice of Intent to Sole Source MP201 Drug Synthesis
Closed Special Notice Posted
- Solicitation number
- HT9425-24-Q-0095
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Silver Spring, Maryland 20910, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) has published a Special Notice indicating its intent to negotiate solely with Mitochon Pharmaceuticals to provide synthesis of the prodrug of 2,4-dinitrophenol (DNP) called MP201. This requirement is in support of WRAIR's Blast Induced Neurotrauma Branch's study on the efficacy of the drug MP201 for ocular dysfunction caused by blast exposure.
The purpose of this Special Notice is to determine if a competitive procurement is in the best interest of the Government. The Special Notice provides key details such as the deadline of July 26, 2024 for interested parties to respond in writing with clear and convincing evidence of their ability to provide the required items. The Special Notice also specifies the North American Industry Classification System (NAICS) code of 541715 with a size standard of 1000. If no other written responses are received by the deadline, the purchase will be awarded to Mitochon Pharmaceuticals without further notice.
Notice text
The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Mitochon Pharmaceuticals,970 Cross Ln, Blue Bell, PA 19422, to provide synthesis of the prodrug of 2,4-dinitrophenol (DNP) called MP201, against ocular dysfunction caused by blast exposure, for WRAIR’s Blast Induced Neurotrauma Branch’s (BINT) study on the efficacy of the drug MP201 by data interpretation/analysis, preparation of quarterly reports, annual progress reports, manuscripts, and final project report.. The MP201 required for this study, is developed and synthesized by Mitochon Pharmaceuticals and is not available through any other source.
The North American Industry Classification System (NAICS) for this requirement is 541715 and the size standard is 1000.
This announcement constitutes the only notice by the government; a written solicitation will not be issued. All sources that believe they are eligible to provide these items must respond in writing. Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes. Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Dawn Jennings at dawn.v.jennings.civ@health.mil.
Interested concerns must identify their capability in writing to the above e-mail address or by mail to the address listed below no later than 12:00PM ET, July 26, 2024. Contracting Office Address:
US Army Medical Research Acquisition Activity, ATTN: FCMR-ACO-AA, 808 Schreider Street, Frederick, MD 21702-5014
Point of Contact:
Dawn Jennings
Dawn.v.jennings.civ@health.mil
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Special Notice | |
| MP201 Drug Synthesis | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | No set-aside | |
| Notice of Intent DNA Synthesizer | — | No set-aside | |
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | Total Small Business | |
| NOTICE OF INTENT TO SOLE SOURCE for the Development of a Handheld Device for Rapid Assessment of Burn Sepsis Risk | — | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity